Tag: PhaseBio

May 27, 2020 Off

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

By BusinessWire

PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP)

May 12, 2020 Off

PhaseBio reports net loss of $14.9 million in Q1 2020

By BusinessWire

PhaseBio reported a net loss of $14.9 million for the three months ended March 31, 2020, which compared with a net loss of $7.3 million for the same period in 2019, which resulted in a net loss of $0.52.